At a glance
ClinicalIndex Comparison Record- ✓Newly diagnosed supratentorial glioblastoma with tissue diagnosis from resection or biopsy, including prior low-grade astrocytoma upgraded to GBM
- ✓Age 18 years or older
- ✓Karnofsky performance score 70 or higher
- ✓Completed standard chemoradiation (60 Gy in 30 fractions with concurrent temozolomide 75 mg/m² daily) within the last 21 days
- ✕Leptomeningeal disease
- ✕Prior treatment with bevacizumab or any checkpoint immune blockade therapies
- ✕Radiotherapy completed more than 3 weeks prior to baseline
- ✕Prior organ transplantation including allogeneic stem cell transplantation
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Avelumab in Patients With Newly Diagnosed Glioblastoma Multiforme
In Brief
A Phase 2 clinical trial evaluating avelumab for Glioblastoma Multiforme of Brain. Completed, enrolled 38 participants across 1 site.
Detailed Summary
This is a safety and tolerability study looking at the addition of avelumab, an immune checkpoint inhibitor, to standard therapy of temozolomide and radiotherapy in patients with newly diagnosed glioblastoma multiforme. All patients will be receiving active therapy. Patients will begin the avelumab within 3 weeks of finishing their radiotherapy. Avelumab will be given at a dose of 10mg/kg IV every 2 weeks concomitantly with the monthly temozolomide. Avelumab will be continued for a total of 52 weeks.
Study Details
Timeline
Interventions
add on of avelumab 10mg/kg IV to standard therapy